Roche Advances Experimental Eye Therapy as Regulators Review Application
Swiss pharmaceutical company Roche has reported encouraging one-year clinical results for vamikibart, an experimental medicine being developed for a sight-threatening eye condition associated with inflammation. Findings from two Phase III studies indicate that improvements in patients’ vision and reductions in retinal swelling were maintained through 52 weeks, strengthening the case for further regulatory review of the treatment. The drug remains investigational and is not yet approved for routine use.
The Basel-based company presented the findings on October 10 at the 2026 annual meeting of the American Academy of Ophthalmology in New Orleans. The results came from the MEERKAT and SANDCAT trials, which compared vamikibart with a sham procedure designed to mimic an injection into the eye. Roche said the studies showed sustained benefits, while the US Food and Drug Administration has accepted its application and is expected to decide on approval by July 2027.
The findings could matter for people living with uveitic macular edema, a condition in which inflammation causes fluid to accumulate in the macula, the central part of the retina responsible for detailed vision. However, the results do not yet establish that the medicine will be approved or that every patient will experience the same improvement.
Why the condition can threaten sight
Uveitis is inflammation inside the eye. When it leads to fluid buildup in the macula, the resulting condition is known as uveitic macular edema, or UME. Swelling in this part of the retina can interfere with central vision, making everyday activities such as reading, driving and recognizing faces more difficult.
The condition can be particularly challenging because treatment must address both inflammation and its effects on the retina. Roche says UME is a leading cause of moderate-to-severe vision loss among people with uveitis and that it predominantly affects working-age adults. The company cites research suggesting that approximately 20% of patients with UME progress to sustained blindness within three years of diagnosis.
Current treatment often relies on corticosteroids, including therapies administered locally to the eye. These medicines can control inflammation, but prolonged steroid exposure may increase pressure inside the eye and raise the risk of glaucoma or cataracts. Treatment decisions therefore involve balancing control of the underlying inflammation against potential complications.
The need for additional options has encouraged research into treatments that target specific biological pathways rather than relying on steroids alone.
How vamikibart is designed to work
Vamikibart is an investigational monoclonal antibody developed for administration by injection into the eye. It targets interleukin-6, or IL-6, a signaling protein involved in the inflammatory process associated with UME. By targeting this pathway, the medicine is intended to address inflammation contributing to the disease.
Roche is developing the drug as a potential non-steroid treatment. That distinction could be important if future evidence confirms that it can control the condition while avoiding some of the long-term risks associated with steroid-based approaches.
The treatment has already been studied in an earlier Phase I trial known as DOVETAIL. Results from that study supported further investigation, leading Roche to launch the two larger Phase III programs.
A targeted mechanism, however, does not guarantee better outcomes or eliminate the possibility of side effects. Regulators will need to evaluate the complete clinical evidence, including the magnitude and durability of benefits, safety findings and the appropriate patient population.
What the two Phase III studies found
MEERKAT and SANDCAT were designed as randomized, double-masked, multicenter trials comparing vamikibart with a sham injection procedure. Participants received one of two doses — 0.25 milligrams or 1 milligram — or the sham procedure during the initial treatment period, which lasted up to 16 weeks. After that, treatment could be given as needed through week 52.
The primary endpoint assessed at week 16 was the proportion of participants who gained at least 15 letters on a standardized best-corrected visual acuity chart. The studies also assessed changes in average visual acuity and central subfield thickness, a measurement used to evaluate swelling in the retina.
The latest one-year results indicate that a numerically higher proportion of patients receiving vamikibart achieved vision gains than those in the sham groups in both trials. Roche also reported that improvements in average visual acuity and reductions in retinal thickness were sustained over the 52-week period.
One practical finding concerned treatment frequency. Approximately two-thirds of eligible patients did not require another injection after the initial 16-week phase. Among those who did need additional treatment, most required only one further injection, according to the company.
This could indicate a manageable treatment burden for some patients, although individual needs may differ. The findings should also be interpreted in the context of the full trial data, rather than as a guarantee that patients could stop treatment after four months.
Regulatory review is now underway
Roche has submitted a Biologics License Application to the FDA, which has accepted the filing. The agency is expected to make its decision by July 2027. Regulatory applications have also been submitted and accepted in the European Union, China and Japan, the company said.
Acceptance of an application means the regulator has agreed to review the submission; it is not an approval decision. The FDA will still need to assess the evidence supporting the drug’s safety and effectiveness before deciding whether it can be marketed for UME in the United States.
If authorized, vamikibart could become a new targeted, non-steroid option for people with the condition. The potential clinical role and any prescribing restrictions would depend on the final regulatory decisions and approved product information.
The latest results build on the initial Phase III findings presented in 2025. Those earlier analyses showed improvements across several measures, although the primary endpoint results differed between the two trials. The one-year data add information about whether benefits can be maintained over time, but do not remove the need for careful assessment of the full evidence.
What the results mean for patients and Roche
For patients, the central question is whether the treatment can preserve or improve vision while reducing the complications and ongoing burden associated with existing options. The reported results are promising, but further regulatory review remains essential, and the medicine should not be regarded as an available replacement for current treatment.
For Roche, the program represents another investment in ophthalmology, an area in which the company develops medicines and delivery technologies for diseases affecting the retina and other parts of the eye. The outcome of the vamikibart review will depend on the clinical evidence and regulators’ conclusions, not solely on the company’s interpretation of the results.
The next major milestone is the FDA’s expected decision by July 2027. Until then, the one-year findings offer evidence of sustained clinical effects in two large-stage trials, while leaving important questions about approval and eventual use unresolved.
